MAX Surgical Specialty Management: Footprint & Growth

Most dental support organizations cast a wide net across general dentistry and a grab-bag of specialties. MAX Surgical Specialty Management took the opposite path: it picked one of the highest-acuity, highest-margin niches in dentistry — oral and maxillofacial surgery (OMS) — and built a regionally dense platform around it. Launched in the fall of 2022 and based in Hackensack, New Jersey, MAX describes itself as the Northeast's first OMS-only management services organization, assembled around a surgeon-led, autonomy-first model rather than a centralized national chassis.

For investors tracking specialty consolidation, MAX is a useful case study in the "focused roll-up" thesis: concentrate capital and operational support inside a single specialty and a single region, then compound through add-on partnerships. This profile looks at how the platform is structured, what its footprint appears to be, how quickly it has grown, and how it sits against the handful of other OMS roll-ups now competing for the same surgeon partners.

Overview

MAX is a management services organization (MSO) built exclusively for oral and maxillofacial surgery practices. The MSO model is familiar across dental and physician services: the management company owns the non-clinical business — operations, finance, marketing, technology, real estate, recruiting — while licensed surgeons retain clinical control of their practices. What distinguishes MAX from the broad, multi-specialty dental support organizations — and even from larger single-specialty peers like U.S. Oral Surgery Management — is its deliberate narrowing to a single specialty and a single contiguous region.

The company was founded by Dr. Jason Auerbach, an oral and maxillofacial surgeon who built Riverside Oral Surgery in New Jersey starting in 2007 and used that group as the platform's anchor practice.¹ MAX positions its pitch to surgeons around clinical autonomy and proximity: rather than outsourcing support from a distant national headquarters, it emphasizes a localized support model with people on the ground in the markets it serves.² That framing — independence plus hands-on regional support — is the core of how MAX recruits practices that might otherwise stay independent or sell to a larger, more centralized DSO.

This emphasis on a surgeon-led structure mirrors the equity-partnership approach used by several peers in the space, including Allied OMS, where partnering surgeons retain meaningful ownership rather than simply selling and exiting.

Company Snapshot

• Headquarters: Hackensack, New Jersey (Bergen County)
• Founded: September 2022¹
• Model: Surgeon-led management services organization (MSO); OMS-only
• Specialty focus: Oral and maxillofacial surgery
• Geography: Northeast — New Jersey, New York, Pennsylvania, Vermont, Connecticut¹
• Anchor practice: Riverside Oral Surgery (founded by Dr. Jason Auerbach, 2007)¹
• Leadership: Dr. Jason Auerbach (Founder & Co-CEO) and Mark Censoprano (Co-CEO); MedEquity founding partner Jeff Ward served as a co-CEO in the platform's early period¹
• Financial sponsors: MedEquity Capital, RF Investment Partners, and Kian Capital¹
• Debt capital: an approximately $77 million senior credit facility from Freeport Financial Partners, announced in 2025²

MAX's investor group is concentrated in the lower-middle market. MedEquity Capital, a Wellesley, Massachusetts healthcare private equity firm, is described as having invested more than $400 million of equity capital over roughly two decades; RF Investment Partners and Kian Capital round out the backing as flexible-capital partners to founder-led companies.¹ The platform has not publicly disclosed enterprise value or revenue, so any sizing beyond its reported footprint should be treated as an estimate.

Footprint Analysis

MAX's footprint is best read as a snapshot that has moved quickly, so the numbers below are company-reported and point-in-time rather than audited. By the company's own account, as of spring 2025 MAX operated approximately 29 practice locations across five states, with the largest concentration in New Jersey (roughly 18 locations), followed by New York (about four), Vermont and Pennsylvania (about three each), and Connecticut (one).² Headcount was reported to have nearly doubled to more than 300 people over the prior 15 months.²

A few cautions on reading these figures. First, location counts and surgeon counts are different measures and should not be conflated — a single partner practice can carry multiple offices, and MAX's anchor group, Riverside Oral Surgery, alone has been described as operating nine to ten locations.¹ Second, the platform has continued adding partnerships since those spring 2025 figures were published, including entries deeper into New York City and the Hudson Valley and additional New Jersey practices, so the current footprint is reasonably read as larger than the last clean total MAX disclosed.¹ Because MAX has not published an updated consolidated count, the prudent diligence posture is to treat "roughly 29-plus locations across five Northeastern states" as a floor rather than a precise current tally.

Geographically, the concentration is the point. MAX has stayed inside a single, contiguous Northeast corridor anchored in New Jersey, which supports its proximity argument and creates the kind of referral and recruiting density that is harder to replicate from a national hub.

Growth History

MAX's growth curve has been steep and well-documented through its own announcements. The rough timeline, using company-reported figures at each milestone:

• September 2022: Platform established around Riverside Oral Surgery as the anchor.¹
• January 2024: Reported roughly 20 locations and about 27 surgeons across three states, with first expansion into New York and Vermont via partners including New York Oral, Maxillofacial, and Implant Surgery (NYOMIS) and two Vermont groups.³
• February 2024: Announced the completion of four acquisitions, reporting approximately 28 surgeons across 21 locations in four states and signaling an intent to roughly double during 2024.³
• November 2024: Reported about 25 locations and 37 surgeons across five states after entering Connecticut and adding partners in New York and Vermont.¹
• 2025: Closed an approximately $77 million senior credit facility, reported roughly 29 locations and 300-plus total headcount, and was named to an industry "emerging groups to watch" list.²
• Late 2025-early 2026: Continued add-on partnerships, including a landmark New York City entry and further New Jersey and Hudson Valley additions.¹

The pattern is classic platform-and-add-on: a credible anchor practice, an early infusion of equity, geographic expansion into adjacent states, and then a debt facility to fund the next wave of partnerships. The reported headcount nearly doubling inside roughly a year is consistent with a company prioritizing land-grab growth over slow, organic build-out.

Competitive Landscape

OMS has quietly become one of the most actively consolidated specialties in dentistry, and MAX is competing for surgeon partners against several well-capitalized platforms. The closest structural comparisons are the other surgeon-equity OMS roll-ups: U.S. Oral Surgery Management, one of the largest and earliest national OMS platforms; Allied OMS, which similarly emphasizes a partner-ownership model; and Beacon Oral Specialists, another multi-state OMS group.⁴ Specialty1 Partners is also active in OMS and adjacent surgical specialties.

MAX's differentiation rests on two related ideas. The first is single-specialty focus: where some platforms pursue multi-specialty or multi-state scale, MAX has stayed exclusively in OMS. The second is regional density over national reach — MAX argues that a localized, in-region support model delivers faster response, easier clinical collaboration, and a recruiting edge that a centralized national operator may find harder to match.² These are genuine, if not unique, points of difference; most of the national platforms would argue scale brings its own advantages in purchasing, payer leverage, and back-office sophistication.

For a partnering surgeon, the practical choice often comes down to autonomy, deal economics, and cultural fit rather than headline size — which is why a regionally concentrated player like MAX can win partners even against larger national competitors. It is worth noting that broader multi-specialty platforms such as Specialized Dental Partners also touch the surgical-specialty market, widening the field of potential acquirers a selling practice might consider.

Market Position

MAX occupies a defensible niche: the leading dedicated OMS consolidator in a single, affluent, densely populated region. That position has clear strengths. OMS is a high-acuity specialty with strong procedure economics, the Northeast corridor offers dense referral networks, and a focused brand can recruit surgeons who value staying within their specialty and region. The surgeon-led, autonomy-forward pitch is well-suited to attracting established practice owners who are not ready to disappear into a national chain.

The same focus carries the usual concentration considerations that diligence should weigh rather than dismiss. A five-state, single-specialty footprint means exposure to regional payer dynamics, state-level regulatory shifts, and a finite pool of attractive OMS practices for which MAX is bidding alongside national platforms. Growth funded partly by debt — the reported senior credit facility — adds the standard sensitivity to interest rates and integration execution that accompanies any leveraged roll-up. None of these are unusual for the model; they are simply the levers an investor would stress-test.

The key forward question is whether MAX deepens its Northeast density toward a clear regional moat or eventually pushes into new geographies and confronts the same national operators head-on. Either path is plausible, and the platform's trajectory so far suggests management is comfortable moving quickly.

TMR Take: MAX Surgical Specialty Management is a clean expression of the focused-roll-up thesis — one specialty, one region, a surgeon-equity model, and a fast add-on cadence backed by lower-middle-market sponsors and a senior credit facility. For operators, the appeal is real: clinical autonomy plus in-region operational support, without the distance of a national DSO. For investors, MAX reads as an attractively concentrated platform whose strengths (specialty focus, regional density, surgeon alignment) are also its risk axes (geographic concentration, a finite Northeast target pool, and leveraged growth). The figures here are company-reported and move quickly, so confirm the current location and surgeon counts, the capital structure, and partner-economics directly before underwriting. The strategic logic, though, is coherent — and OMS remains one of the more investable corners of dental specialty consolidation.

Sources

1. MAX Surgical Specialty Management — company website and press releases.

2. Group Dentistry Now — dental group industry coverage.

3. Business Wire and PR Newswire — company transaction announcements.

4. Industry coverage of OMS consolidation — Group Dentistry Now and platform disclosures.